What Wall Street is saying about AVEO Pharmaceuticals, Inc. (AVEO)

What Wall Street is saying about AVEO Pharmaceuticals, Inc. (AVEO)

What Wall Street is saying about AVEO Pharmaceuticals, Inc. (AVEO)

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock is presently standing at about $2.22 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 2 analysts covering the company is $2.50, which suggests the stock could still rise over 11 percent. The highest analyst price target is $3.00, which implies a rally of 65 percent. And a quick view of analyst notes show that 1 are rating the stock a buy while 1 rate AVEO a strong buy. There are 0 equity research firms advocating a Hold and 0 consider it Sell.

Piper Jaffray analysts provided their view on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) recently. The rating firm issued a Overweight rating to this company in a research note released on May 19, 2016. FBR Capital analysts disclosed their opinion on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) recently. The rating firm gave a Outperform rating to this stock in a research note published on Mar 30, 2016. According to a research note disclosed on Mar 09, 2015, analysts at RBC Capital Mkts have upped their rating on these shares from Underperform to Sector Perform.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Transactions Roundup

Several insiders were part of recent insider activity for the stock. Its 10% Owner Sonsini Peter W. Purchased 16,362,694 company shares for 3,000,000, in a transaction on Mar 28. Following the transaction, the 10% Owner is left with a stake of 6,000,000 shares, currently valued at $13,320,000. Meanwhile, 10% Owner Viswanathan Ravi purchased 16,362,694 shares worth $3,000,000, through a transaction dated Mar 28. Following the completion of the transaction, the insider is left with a stake of 6,000,000 shares, amounting $13,320,000. AVEO 10% Owner Sakoda Jon also purchased 16,362,694 shares, at a stock price of $0.50. This transaction occurred on Mar 28 totals $3,000,000. After this transaction, the insider’s stake stands at 6,000,000 shares, with a market value of $13,320,000.

Executives hold 2.15 percent of the stock. NEA MANAGEMENT COMPANY, LLC is one of the biggest insider owners in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 16,362,694 shares which have current market value of around $36,325,181.PERCEPTIVE ADVISORS LLC is another major inside shareholder in the company. The insider owns 5,108,808 shares as of 03/31/2017, currently worth $11,341,554. ARMISTICE CAPITAL, LLC is ranked as third insider holder of the stock. This insider holds 4,800,000 shares with a market value around $10,656,000 as of recent close.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Earnings Outlook

In AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s latest quarter, EPS moved to $-0.12 from $-0.07 in preceding quarter and revenues reached at $2.53M compared to $0.13M. Analysts had expected AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to post net income of about $-0.12 per share on $0.12M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in the range of $-0.17 to $-0.09. That is compared with the $-0.13 in EPS it reported during the same period a year ago.